Dermatology

Filter

Value of Achieving Minimal Disease Activity in Atopic Dermatitis

March 2026

AD is a common, chronic inflammatory skin disease with a significant impact on patients’ lives.1 As a heterogeneous disease, AD has…

Anti-IL-23 Blocks Pathogenic T Cells

Psoriasis affects 60 million people globally. It is an inflammatory skin condition that can significantly impact quality of life…

The Evolving Atopic Dermatitis Treatment Landscape

Experts provide real-life insights and case examples of managing moderate-to-severe atopic dermatitis, sharing their treatment experience with lebrikizumab.

Acne Treatment Review and Present Perspectives

Acne is a chronic inflammatory skin disease whose visible effects can have a significant psychological impact on patients. A multimodal…

Retracted: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data

This article has now been retracted and a retraction statement has been published.

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

30 Jan 2025

Vitiligo, Beyond White Patches

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis and…

17 Dec 2024

Tralokinumab in the Era of Disruption in Atopic Dermatitis

Gain valuable insights from three atopic dermatitis (AD) specialists who specifically consider one of the newest systemic therapies that targets the cytokine IL-13, a key cytokine involved in the pathogenesis of AD.

Epigenetics to Reverse Skin Ageing

Epigenetic changes drive skin aging by silencing the expression of youthful genes. Experts discussed the discovery of epicelline, an…

Loading posts...

« Previous 1 2 3 4 5 6 … 31 Next »